Hospitalization for invasive pneumococcal disease in a national sample of children with sickle cell disease before and after PCV7 licensure

Timothy L. Mccavit, Lei Xuan, Song Zhang, Glenn Flores, Charles T. Quinn

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Objective: To estimate national hospitalization rates for invasive pneumococcal disease (IPD) in children with sickle cell disease (SCD) before and after the 2000 licensure of the heptavalent pneumococcal conjugate vaccine (PCV7). Procedure: We performed a retrospective trend analysis of the 1994-2007 Nationwide Inpatient Sample databases. Hospitalizations involving children with SCD and IPD were identified by ICD-9CM code. The primary outcomes, the annual hospitalization rate for IPD in children with SCD and the proportion of hospitalizations for IPD per 100 total SCD hospitalizations, were analyzed using multivariable linear regression and contingency analysis, respectively. Results: A total of 1,242 hospitalizations for IPD in SCD patients were identified from 1994-2007, with a mortality rate of 2.4%. The national mean annual rate of IPD hospitalization decreased by 65%, from 131.8cases/year from 1994 to 2000 to 45.5cases/year from 2001 to 2007 (P=0.001). The national proportion of hospitalizations for IPD per 100 total SCD hospitalizations decreased from 0.4 to 0.15 (P<0.0001) over the same interval. Following PCV7 licensure, the mean annual cumulative hospital days and cumulative hospital charges decreased nationally by 53% and 36%, respectively. Conclusion: In a national sample, PCV7 licensure is temporally associated with a nearly threefold reduction in IPD hospitalizations in children with SCD.

Original languageEnglish (US)
Pages (from-to)945-949
Number of pages5
JournalPediatric Blood and Cancer
Volume58
Issue number6
DOIs
StatePublished - Jun 2012

Fingerprint

Sickle Cell Anemia
Licensure
Hospitalization
Hospital Charges
International Classification of Diseases
Inpatients
Linear Models
Regression Analysis
Databases
Mortality

Keywords

  • Hospitalization
  • Infection
  • PCV7
  • Sickle cell disease
  • Streptococcus pneumoniae

ASJC Scopus subject areas

  • Oncology
  • Pediatrics, Perinatology, and Child Health
  • Hematology

Cite this

Hospitalization for invasive pneumococcal disease in a national sample of children with sickle cell disease before and after PCV7 licensure. / Mccavit, Timothy L.; Xuan, Lei; Zhang, Song; Flores, Glenn; Quinn, Charles T.

In: Pediatric Blood and Cancer, Vol. 58, No. 6, 06.2012, p. 945-949.

Research output: Contribution to journalArticle

@article{386d929f9a2742feb1d2286e3dc2d4f2,
title = "Hospitalization for invasive pneumococcal disease in a national sample of children with sickle cell disease before and after PCV7 licensure",
abstract = "Objective: To estimate national hospitalization rates for invasive pneumococcal disease (IPD) in children with sickle cell disease (SCD) before and after the 2000 licensure of the heptavalent pneumococcal conjugate vaccine (PCV7). Procedure: We performed a retrospective trend analysis of the 1994-2007 Nationwide Inpatient Sample databases. Hospitalizations involving children with SCD and IPD were identified by ICD-9CM code. The primary outcomes, the annual hospitalization rate for IPD in children with SCD and the proportion of hospitalizations for IPD per 100 total SCD hospitalizations, were analyzed using multivariable linear regression and contingency analysis, respectively. Results: A total of 1,242 hospitalizations for IPD in SCD patients were identified from 1994-2007, with a mortality rate of 2.4{\%}. The national mean annual rate of IPD hospitalization decreased by 65{\%}, from 131.8cases/year from 1994 to 2000 to 45.5cases/year from 2001 to 2007 (P=0.001). The national proportion of hospitalizations for IPD per 100 total SCD hospitalizations decreased from 0.4 to 0.15 (P<0.0001) over the same interval. Following PCV7 licensure, the mean annual cumulative hospital days and cumulative hospital charges decreased nationally by 53{\%} and 36{\%}, respectively. Conclusion: In a national sample, PCV7 licensure is temporally associated with a nearly threefold reduction in IPD hospitalizations in children with SCD.",
keywords = "Hospitalization, Infection, PCV7, Sickle cell disease, Streptococcus pneumoniae",
author = "Mccavit, {Timothy L.} and Lei Xuan and Song Zhang and Glenn Flores and Quinn, {Charles T.}",
year = "2012",
month = "6",
doi = "10.1002/pbc.23259",
language = "English (US)",
volume = "58",
pages = "945--949",
journal = "Pediatric Blood and Cancer",
issn = "1545-5009",
publisher = "Wiley-Liss Inc.",
number = "6",

}

TY - JOUR

T1 - Hospitalization for invasive pneumococcal disease in a national sample of children with sickle cell disease before and after PCV7 licensure

AU - Mccavit, Timothy L.

AU - Xuan, Lei

AU - Zhang, Song

AU - Flores, Glenn

AU - Quinn, Charles T.

PY - 2012/6

Y1 - 2012/6

N2 - Objective: To estimate national hospitalization rates for invasive pneumococcal disease (IPD) in children with sickle cell disease (SCD) before and after the 2000 licensure of the heptavalent pneumococcal conjugate vaccine (PCV7). Procedure: We performed a retrospective trend analysis of the 1994-2007 Nationwide Inpatient Sample databases. Hospitalizations involving children with SCD and IPD were identified by ICD-9CM code. The primary outcomes, the annual hospitalization rate for IPD in children with SCD and the proportion of hospitalizations for IPD per 100 total SCD hospitalizations, were analyzed using multivariable linear regression and contingency analysis, respectively. Results: A total of 1,242 hospitalizations for IPD in SCD patients were identified from 1994-2007, with a mortality rate of 2.4%. The national mean annual rate of IPD hospitalization decreased by 65%, from 131.8cases/year from 1994 to 2000 to 45.5cases/year from 2001 to 2007 (P=0.001). The national proportion of hospitalizations for IPD per 100 total SCD hospitalizations decreased from 0.4 to 0.15 (P<0.0001) over the same interval. Following PCV7 licensure, the mean annual cumulative hospital days and cumulative hospital charges decreased nationally by 53% and 36%, respectively. Conclusion: In a national sample, PCV7 licensure is temporally associated with a nearly threefold reduction in IPD hospitalizations in children with SCD.

AB - Objective: To estimate national hospitalization rates for invasive pneumococcal disease (IPD) in children with sickle cell disease (SCD) before and after the 2000 licensure of the heptavalent pneumococcal conjugate vaccine (PCV7). Procedure: We performed a retrospective trend analysis of the 1994-2007 Nationwide Inpatient Sample databases. Hospitalizations involving children with SCD and IPD were identified by ICD-9CM code. The primary outcomes, the annual hospitalization rate for IPD in children with SCD and the proportion of hospitalizations for IPD per 100 total SCD hospitalizations, were analyzed using multivariable linear regression and contingency analysis, respectively. Results: A total of 1,242 hospitalizations for IPD in SCD patients were identified from 1994-2007, with a mortality rate of 2.4%. The national mean annual rate of IPD hospitalization decreased by 65%, from 131.8cases/year from 1994 to 2000 to 45.5cases/year from 2001 to 2007 (P=0.001). The national proportion of hospitalizations for IPD per 100 total SCD hospitalizations decreased from 0.4 to 0.15 (P<0.0001) over the same interval. Following PCV7 licensure, the mean annual cumulative hospital days and cumulative hospital charges decreased nationally by 53% and 36%, respectively. Conclusion: In a national sample, PCV7 licensure is temporally associated with a nearly threefold reduction in IPD hospitalizations in children with SCD.

KW - Hospitalization

KW - Infection

KW - PCV7

KW - Sickle cell disease

KW - Streptococcus pneumoniae

UR - http://www.scopus.com/inward/record.url?scp=84863338459&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863338459&partnerID=8YFLogxK

U2 - 10.1002/pbc.23259

DO - 10.1002/pbc.23259

M3 - Article

VL - 58

SP - 945

EP - 949

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

SN - 1545-5009

IS - 6

ER -